Gossamer Bio, Inc. (GOSS) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is mixed: Ten analysts give Gossamer Bio an average “Hold” rating, with five buys, three holds and two sells. The average one-year price target is $256.00.
• Institutional ownership is substantial: Institutional investors own 81.23% of the company, with several funds recently increasing or initiating positions.
• The stock has declined sharply: GOSS opened at $8.90, near its 52-week low of $8.77, versus a 52-week high of $309.60. Gossamer Bio is a clinical-stage biotechnology company whose lead candidate is seralutinib, an inhaled drug targeting pulmonary vascular remodeling.

Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) has received an average rating of "Hold" from the ten analysts that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $256.00.

A number of equities analysts have recently issued reports on the company. Leerink Partners upgraded Gossamer Bio from a "market perform" rating to an "outperform" rating and set a $80.00 price target on the stock in a research note on Tuesday, July 28th. Chardan Capital started coverage on Gossamer Bio in a research report on Tuesday. They set a "buy" rating for the company. Wall Street Zen downgraded Gossamer Bio from a "hold" rating to a "sell" rating in a report on Sunday, September 20th. Weiss Ratings raised Gossamer Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 9th. Finally, HC Wainwright reissued a "buy" rating on shares of Gossamer Bio in a research report on Thursday, August 27th.

Hedge Funds Weigh In On Gossamer Bio

Institutional investors have recently made changes to their positions in the business. Corient Private Wealth LP lifted its stake in shares of Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company's stock worth $927,000 after purchasing an additional 1,647,315 shares during the period. Bank of America Corp DE bought a new stake in Gossamer Bio during the second quarter valued at approximately $65,000. Hsbc Holdings PLC grew its position in Gossamer Bio by 1,289.4% during the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company's stock valued at $267,000 after buying an additional 1,469,175 shares during the period. Kalehua Capital Management LLC bought a new stake in Gossamer Bio during the first quarter valued at approximately $3,363,000. Finally, BlackRock Inc. purchased a new stake in Gossamer Bio during the second quarter valued at approximately $1,262,000. Institutional investors own 81.23% of the company's stock.

Gossamer Bio Trading Down 8.8%

Shares of GOSS opened at $8.90 on Thursday. The firm has a fifty day simple moving average of $12.14 and a two-hundred day simple moving average of $17.08. The firm has a market cap of $54.38 million, a PE ratio of -0.16 and a beta of 2.21. Gossamer Bio has a 1-year low of $8.77 and a 1-year high of $309.60.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer's lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.